Jefferies Group LLC set a GBX 4,900 ($66.06) price target on AstraZeneca plc (LON:AZN) in a report released on Monday. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.
Several other research analysts have also issued reports on the company. Liberum Capital lowered AstraZeneca plc from a buy rating to a hold rating and upped their target price for the company from GBX 4,800 ($64.72) to GBX 5,000 ($67.41) in a research report on Thursday, September 14th. J P Morgan Chase & Co reaffirmed a neutral rating and set a GBX 4,500 ($60.67) target price on shares of AstraZeneca plc in a research report on Thursday, September 14th. Barclays PLC set a GBX 6,300 ($84.94) target price on AstraZeneca plc and gave the company a buy rating in a research report on Wednesday, September 13th. Citigroup Inc. set a GBX 6,000 ($80.90) target price on AstraZeneca plc and gave the company a buy rating in a research report on Wednesday, September 13th. Finally, Berenberg Bank reaffirmed a buy rating and set a GBX 5,500 ($74.15) target price on shares of AstraZeneca plc in a research report on Monday, September 11th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of GBX 5,041.09 ($67.97).
Shares of AstraZeneca plc (AZN) opened at 4733.00 on Monday. The company’s 50 day moving average price is GBX 4,568.92 and its 200 day moving average price is GBX 4,884.42. The stock’s market capitalization is GBX 59.92 billion. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00.
TRADEMARK VIOLATION NOTICE: “AstraZeneca plc (AZN) Given a GBX 4,900 Price Target by Jefferies Group LLC Analysts” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://stocknewstimes.com/2017/09/19/astrazeneca-plc-azn-given-a-gbx-4900-price-target-by-jefferies-group-llc-analysts.html.
The firm also recently declared a dividend, which was paid on Monday, September 11th. Investors of record on Thursday, August 10th were issued a GBX 68.90 ($0.93) dividend. The ex-dividend date of this dividend was Thursday, August 10th. This represents a yield of 1.35%.
In other AstraZeneca plc news, insider Nazneen Rahman purchased 39 shares of AstraZeneca plc stock in a transaction that occurred on Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($58.92) per share, with a total value of £1,704.30 ($2,297.83).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.